#AFDD2020

November 18 - 20, 2019
6th Floor Boston Revere Common

3rd Annual
AFDD
Anti-Fibrotic Drug Development

Translating Therapeutic Success Across Clinical Phases and Fibrotic Conditions
The roadmap to anti-fibrotic drug development advancements

36 expert speakers including:

Alexey Lugovskoy
Chief Development Officer
Morphic Therapeutics

Lisa Hazwelwood
Principal Scientist
Research, Liver Disease and Fibrosis
AbbVie

Sydney Montesi
Instructor in Medicine
Harvard University

Tim Johnson
Executive Director
Non-Haemophilia Commercial Assessment
UCB

Anie Philip
Professor Department of Surgery
Research Institute of the McGill University Health Center

Robert Edwards
Director and CVM Clinical Project Specialist
Janssen

Partners:

TherapeutAix
XYLX
Biomodels

14 in-depth case studies
11 hours networking
30 expert speakers
100+ like-minded peers

Tel: (+1) 617 455 4188     Mail: info@hansonwade.com     www.afdd-summit.com
Welcome to the 3rd Annual Anti-Fibrotic Drug Development Summit (AFDD) 2019

The industry’s definitive guide to turning fibrotic mechanisms into clinically effective therapeutics across disease areas

Join over 100 fellow drug developers to disseminate the latest findings, build a comprehensive network of like-minded peers who share the same challenges and search for drug repurposing opportunities.

Hear from pharma and biotech companies of all sizes, as well as clinicians and leading academics for a complete picture of the current challenges and opportunities.

Find commonalities across disease areas that can be applied back at the lab with presentations from specialists across all fibrotic conditions including NASH, IPF, CKD, cardiovascular, gastrointestinal, Scleroderma, rare disease and ocular fibrosis.

The next generation of anti-fibrotic treatments will be born at the 3rd AFDD Summit.

Hear what previous attendees have to say

This conference looks at things from a different angle than others in the field, with the emphasis on industry developments and direction rather than academic research. It was nice to hear from companies developing technologies and solutions to aid research in fibrosis as well as those looking for partners. I enjoyed listening to how different companies tackled problems.

Tim Johnson, Director Fibrotic Remodeling, UCB

Excellent panel of speakers, thought provoking discussions.

Lynn Williams, Group Leader, University of Oxford

Five Unmissable Highlights

Compelling Case Studies
The AFDD Summit provides a forum for leaders to share the newest advancements in drug development for fibrotic conditions.

Diverse Discussions
Our panels bring together multi-specialty, cross background professionals to discuss the biggest challenges faced by the industry and discover the solution together.

Academic Showcase
Look to the future with the latest discoveries from the most prestigious academic institutions.

Productive Networking
From constructive conversations over coffee to dexterous discussions over drinks, our varied networking program has something for everyone.

Hands-on Workshops
We believe in practical learning and nothing champions this better than our 3 hour workshops.
An Unrivaled Speaker Line-Up

Lisa Hazelwood  
Principal Scientist  
Liver Disease and Fibrosis Discovery  
Abbvie

John Atkinson  
Senior Research Scientist  
Tissue Remodelling  
UCB

Richard Stratton  
Consultant Physician and Honorary Senior Lecturer  
University College London

Tim Johnson  
Director Immunology  
Therapeutic Area  
UCB

Ravi Kumar  
Senior Vice President and Chief Scientific Officer  
Acceleron Pharma

Pieter Muntendam  
Chief Executive Officer and Founder  
G3 Pharmaceuticals

Aftab Taiyab  
Research Scientist  
McMaster University

Masha Poyurovsky  
Vice President  
Discover Biology  
Kadmon Corporation LLC

Alexey Lugovskoy  
Chief Development Officer  
Morphic Therapeutics

Sten R. Sörensen  
Chief Executive Officer  
Cereno Scientific

Shervin Assassi  
Professor of Medicine and Co-Director of the UTHealth Scleroderma Program  
University of Texas Health Science Center at Houston

Anie Philip  
Professor Department of Surgery  
Research Institute of the McGill University Health Center

Yaron Ilan  
Director Department of Medicine  
Hebrew University Hadassah Medical Center

Sydney Montesi  
Instructor in Medicine  
Harvard University

Min Lu  
Morphic Therapeutics  
Head of Fibrosis

Timothy J. Pelura Ph.D.  
President & CEO  
OptiKira

Eliezer Zomer Ph.D.  
Vice President  
Drug Discovery and Manufacturing  
Galectin Therapeutics

Lee Borthwick  
Fibrosis Biology Lecturer and Chief Operating Officer  
FibroFind  
Newcastle University

Jean-François Thibodeau  
Research Scientist  
Prometic Biosciences

Gilles Tremblay  
Director Preclinical Development  
Forbius

Mehran Moghaddam  
Chief Executive Officer  
OROX Biosciences
Great conference. Well run, great speakers with experienced insights from the trenches of fibrotic drug development

Tim Pelura, CEO, BioMotiv
Pre-Conference Workshops
Monday November 18 2019

Registration and Welcome Coffee
8:30 – 9:00

Workshop A
9:00 – 12:00

Biomarkers 101
- Novel biomarkers: how to create them and how to apply them
- Hands-on demonstration of biomarker application to preclinical and clinical models
- Medical imaging and blood tests: the pros and cons of the latest technology
- Translating in vivo and in vitro models to clinical trials through consistent biomarker application

Workshop Leader
- Sydney Montesi
  Instructor in Medicine
  Harvard University
- Kristen D’Silva
  Physician
  Massachusetts General Hospital

Lunch Networking Break
12:00 – 13:00

Workshop B
13:00 – 16:00

How to cure multifactorial fibrotic diseases “Kill Two Birds With One Stone: MRI-1867, Hybrid Inhibitor of Peripheral Cannabinoid Receptor 1 (CB1R) & Inducible Nitric Oxide Synthase (iNOS), for the Treatments of NASH & Liver, Lung and Skin fibrosis”
- Outlining rationale for multi-target approach by polypharmacology to develop effective therapies in complex progressive diseases such as NASH and fibrotic diseases
- Identifying dual targeting of peripheral cannabinoid receptor 1 (CB1R) and inducible nitric oxide synthase (iNOS) as an effective therapeutic strategy in obesity, diabetes, AFLD, NAFLD, NASH, liver, lung and skin fibrosis
- Introducing the concept of third-generation cannabinoid receptor 1 (CB1R) antagonists for metabolic and fibrotic disorders
- Demonstrating preclinical efficacy of MRI-1867, an orally bioavailable small molecule antagonist of peripheral CB1R/iNOS, in fibrotic disorders: liver, lung and skin fibrosis

Workshop Leader
- Resat Cinar
  Staff Scientist
  National Institute on Alcohol Abuse and Alcoholism

Workshop C
13:00 – 16:00

Mechanistic workshop: Inhibitors
- Discover fibrotic inducers to create the perfect mechanistic antidote
- Decipher the biological elements lacking in a fibrotic patient but found in a healthy patient
- The creation of inhibiting treatments: from R&D to clinical trials

Workshop Leaders
- Richard Stratton
  Consultant Physician and Honorary Senior Lecturer
  University College London
- Rana Herro
  Junior Faculty Instructor
  La Jolla Institute for Immunology

Networking Coffee to Stay or Go
16:00 – 16:30
### Conference Day One
Tuesday November 19 2019

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00</td>
<td><strong>Registration and Welcome Coffee</strong></td>
</tr>
</tbody>
</table>
|       | **Alexey Lugovskoy**  
Chief Development Officer  
Morphic Therapeutics       |
| 9.00  | **Chair’s Opening Remarks**                                              |
|       | **Keynote Panel Sessions**                                               |
| 9.10  | **Panel: One Vision for the Future of Fibrosis**                         |
|       | • Understand the commonalities between varying fibrotic conditions to better prevent and reduce inflammation  
• Develop a systematic approach to target fibrosis across organs  
• Share data to learn from previous failures and streamline the drug development process  
• Decide whether treatments should be targeting fibrosis as a disease itself or as a response to the disease within that organ  
|       | **Moderator:** Min Lu  
Morphic Therapeutics  
Head of Fibrosis  
**Panellists:**  
Lisa Hazelwood  
Principal Scientist  
Liver Disease and Fibrosis Discovery  
AbbVie  
Tim Johnson  
Director Immunology Therapeutic Area  
UCB  
Timothy J. Pelura  
President and CEO  
OptiKira  |
| 9.50  | **Panel: The Trials and Tribulations of Animal Models**                  |
|       | • Decide whether animal models are necessary or whether they can be bypassed  
• Weigh the relevancy of precision-cut organ slices against the longevity of animal models  
• Consider testing multiple animal models for a smoother transition to clinical trial  
|       | **Moderator:** Alexey Lugovskoy  
Morphic Therapeutics  
Chief Development Officer  
**Panellists:**  
John Atkinson  
Senior Research Scientist  
Tissue Remodelling  
UCB  
Lee Borthwick  
Fibrosis Biology Lecturer and Chief Operating Officer  
FibroFind  
Newcastle University  
Masha Poyurovsky  
Vice President  
Discover Biology  
Kadmon Corporation LLC  |
| 10.30 | **Speed Networking**  
Establish meaningful business connections at a rapid rate. Efficiency at its finest.  
|       | **Research and Discovery Sessions: Novel Targets, Molecules and Pathways** |
| 12.00 | **Case Study: Novel Two Pronged Target Approach**                        |
|       | • Develop unique molecules that attack two targets simultaneously to stop the progression of fibrosis across the body  
• Ensure secondary targets are relevant and do not enhance toxicity of treatment  
|       | **Mehran Moghaddam**  
Chief Executive Officer  
OROX Biosciences       |
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 12.20 | **Disease-Specific Extracellular Matrix Cell Culture Substrates to Improve Predictive in Vitro Models of Fibrosis**  
- Introducing a standardized, fully humanized commercial 3D cell culture platform for fibrosis research  
- Describing the extracellular matrix (ECM) composition of the substrates that recapitulates the human disease environment in vitro  
- Discussing how this platform can reduce the dependence on animal models, and enable more relevant scientific results leading to improved drug discovery process |
| 12.35 | **Therapeutics for Chronic Fibrotic Diseases**  
- The next generation of Galectin-3 inhibitors: from R&D through to phase III clinical trials  
- Discovery of functional allosteric inhibitors |
| 13.00 | **Lunch Networking Break** |
| 14.00 | **Case Study: Therapeutic Integrin Inhibition**  
- Selective integrin inhibitors block TGF-B activation in a cell and tissue specific manner for the treatment of NASH and IPF  
- PK and PD evaluation of dual $\alpha$v$\beta$6/$\alpha$v$\beta$1 inhibitors in humans and primates |
| 14.20 | **Case Study: Galectin-3 as a Potential Treatment Target**  
- Identify patients with galectin-3 mediated fibrogenesis by plasma galectin-3 levels  
- Using the galectin-3 carbohydrate recognition domain as an on-off switch for treatment  
- The promise of galectin-3 inhibition in cardiac and other conditions |
| 14.40 | **Building a platform of evidence that will lead to clinical and partnering success in fibrotic disease**  
- A view of the future clinical landscape in fibrotic disease – exemplified by IPF and NASH, and the ability of currently available assays to address this  
- The opportunity to improve translation via the use of biomarkers  
- Data sets required by industry partners, VCs, PIs and regulators |
| 14.55 | **Case Study: Selective ROCK-2 Inhibitor Programme**  
- ROCK2 as a kinase central to the signalling processes involved in aberrant wound healing and fibrosis  
- Up-regulation in acute and chronic inflammation  
- Inhibition of ROCK2 reduces the pro-fibrotic and pro-inflammatory response disease relevant in vitro and in vivo models |
| 15.15 | **Q&A Panel: Novel Targets, Molecules and Pathways** |
15.40  Afternoon Networking Break

Preclinical Sessions: Translating Biology from Animal to Patient

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 16.10 | **Case Study: Successful Clinical Trials Start with Carefully Curated Animal Models**  
John Atkinson  
Senior Research Scientist Tissue Remodelling  
UCB  
- Specify readouts based on the biology of the target to reflect the chosen mechanism of action  
- Adopt a poly-pharmacy approach for increased effectiveness  
- Move away from inbred strains in animal models and diversify environment and age ranges |
| 16.30 | **Case Study: Next Generation In Vitro Models**  
Lee Borthwick  
Fibrosis Biology Lecturer and Chief Operating Officer  
FibroFind  
Newcastle University  
- Ensure a smoother transition to clinical trial with precision cut slice technology that mimics the function of the organ  
- Recreate the organ culture by replicating the biology and cells that would be found in a person  
- Stimulate the culture with a cause relevant to the chosen clinical disease for authentic progression of fibrosis  
- Use of precision cut slices for the modelling of fibrosis |
| 16.50 | **Case Study: Use of Technology in the Development of TG2 Inhibitory Therapeutics**  
Tim Johnson  
Director Immunology Therapeutic Area  
UCB  
- Development of a glomerular sclerosis organoid model  
- Responses in organoid models which recapitulate rodent in vivo data  
- Creation of CKD primate models for antibody therapies  
- Use of surrogate biomarkers for in vivo studies |
| 17.10 | **Q&A Panel: Translating Biology from Animal to Patient** |

17.30  Poster Session and Drinks Reception  
Constructive conversations over cocktails and canapés to the backdrop of posters.

The only meeting to attend if you want to learn about state of the art developments in fibrosis

Vincenza di Modugno, Director, Roche
Conference Day Two
Wednesday November 20 2019

8.00 Welcome Coffee

Alexey Lugovskoy
Chief Development Officer
Morphic Therapeutics

8.30 Chair’s Opening Remarks

Jean-Francois Thibodeau
Research Scientist
Prometic Biosciences

8.40 Case Study: Novel Compounds to Target Alstrom
Sten R. Sörensen
Chief Executive Officer
Cereno Scientific

9.00 Advancements in Cardiovascular Fibrosis
Gilles Tremblay
Director Preclinical Development
Forbius

9.20 Case Study: Novel Inhibitors of TGF Beta for Fibrotic Cancer
Robert Edwards
Director and CVM Clinical Project Specialist
Janssen

9.40 A Blueprint for Success: J&J’s CREDENCE Clinical Trial
Timothy J. Pelura
President and CEO
OptiKira

10.00 Targeting the Unfolded Protein Response for the Treatment of Fibrotic Disease

10.20 Q&A Panel: Spotlight on Fibrotic Disease Areas & Later Stage Clinical Trial Design

Jean-Francois Thibodeau
Research Scientist
Prometic Biosciences

Sten R. Sörensen
Chief Executive Officer
Cereno Scientific

Gilles Tremblay
Director Preclinical Development
Forbius

Robert Edwards
Director and CVM Clinical Project Specialist
Janssen

11.40 Morning Networking Break

12.10 Panel: Advancements in Metabolic Fibrosis

Combination therapies for NASH and Chronic Kidney Disease
The relationship between diabetes and CKD – can common therapies be effectively used to treat both conditions?
Tissue targeting in CKD – increasing efficacy, reducing toxicity
Novel molecular targets including Galectin-3 inhibitors and HSP47

 Moderator: Min Lu
Morphic Therapeutics
Head of Fibrosis

Panelists:
Tim Johnson
Director Immunology
Therapeutic Area UCB

Lisa Hazelwood
Principal Scientist
Liver Disease and Fibrosis Discovery Abbvie

Resat Cinar
Staff Scientist
National Institute on Alcohol Abuse and Alcoholism

Spotlight on Fibrotic Disease Areas & Clinical Trial Design

8.40 Case Study: Novel Compounds to Target Alstrom
• Develop a drug that works through binding activation and inhibition of receptors found in macrophages and immune cells
• Target the initial inflammatory process to prevent the progression of fibrotic disease

9.00 Advancements in Cardiovascular Fibrosis
• Epigenetics of CV fibrosis and disease
• Repurposing of Valproic Acid (VPA)
• VPA in CV fibrosis
• Epigenetic modulation with VPA - “Gene therapy” for CV fibrosis on population level

9.20 Case Study: Novel Inhibitors of TGF Beta for Fibrotic Cancer
• Tackle the barrier created by fibroblasts in the tumour microenvironment which prevents immune cells from targeting cancerous cells
• Understand the role of TGF Beta within fibrotic cancers and create a novel inhibitor of TGF Beta Ligands
• Consider the role of stromal components and the secretion of cytokines within cancer fibroblast to find a combined immune checkpoint and TGF Beta inhibitors treatment

9.40 A Blueprint for Success: J&J’s CREDENCE Clinical Trial
• Patient recruitment: a global multidisciplinary effort required perseverance
• Adjudication: a concerted cross-functional effort required diligence and determination
• Patient retention: a top priority from Day 1 left no stone unturned

10.00 Targeting the Unfolded Protein Response for the Treatment of Fibrotic Disease
• Significance of the unfolded protein response in various fibrotic diseases
• Epithelium, fibroblast, macrophage?...all of the above
• Representative preclinical data and path forward
### 12.50 Panel: You Can’t Teach an Old Pathway New Tricks; the Case for and Against TGF Beta as a Primary Target for Fibrosis and Fibrotic Cancers

- Can inhibiting TGF Beta alone stop the progression of fibrosis?
- Does the reduction of TGF Beta in animal models result in strong histological end points at clinical trial?
- Is there a common TGF Beta pathway to target which will attack fibrotic cancers?

<table>
<thead>
<tr>
<th>Moderator:</th>
<th>Panellists:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gilles Tremblay</td>
<td>Ravi Kumar</td>
</tr>
<tr>
<td>Director Preclinical Development Forbius</td>
<td>Senior Vice President and Chief Scientific Officer</td>
</tr>
<tr>
<td></td>
<td>Acceleron Pharma</td>
</tr>
<tr>
<td>Scott Turner</td>
<td>Patrick Andre</td>
</tr>
<tr>
<td>Vice President Translational Sciences</td>
<td>Vice President Biology</td>
</tr>
<tr>
<td>Pliant Therapeutics</td>
<td>Acceleron</td>
</tr>
</tbody>
</table>

| 13.30 | Lunch Break |

### 14.30 Wrap Up Roundtables

9 tables, 9 problems, 9 solutions. Ready, set, resolve!

**Inhibitors vs inducers: create a plan to develop either an inhibiting or inducing anti-fibrotic treatment. Explain why you selected the inhibitor/inducer**

- **Masha Poyurovsky**
  - Vice President Discover Biology
  - Kadmon Corporation LLC

**Design a novel biomarker and explain its application to both the preclinical and clinical stage**

- **Jean-Francois Thibodeau**
  - Research Scientist
  - Prometic Biosciences

**Design a preclinical plan with only in vitro models**

- **John Atkinson**
  - Senior Research Scientist
  - Tissue Remodelling
  - UCB

**Incorporate the use of technology into the development of an anti-fibrotic drug**

- **Scott Turner**
  - Vice President Translational Sciences
  - Pliant Therapeutics

**Develop a treatment for a patient with fibrotic cancer**

- **Min Lu**
  - Morphic Therapeutics
  - Head of Fibrosis

**Translate J&J’s CREDENCE trial into a clinical trial design for an anti-fibrotic treatment**

- **Robert Edwards**
  - Director and CVM Clinical Project Specialist
  - Janssen

**Select a pathway outside of TGF Beta to target in the treatment of fibrosis – define the drug development plan for this pathway**

- **Mehran Moghaddam**
  - Chief Executive Officer
  - OROX Biosciences

**Define a common mechanism to target in order to create an anti-fibrotic drug which will treat all fibrotic disease areas**

- **Shervin Assassi**
  - Professor of Medicine and Co-Director of the UTH Health Scleroderma Program
  - University of Texas Health Science Center at Houston

**Incorporate the use of technology into the development of an anti-fibrotic drug**

- **Ravi Kumar**
  - Senior Vice President and Chief Scientific Officer
  - Acceleron Pharma

**Incorporate the use of technology into the development of an anti-fibrotic drug**

- **Patrick Andre**
  - Vice President Biology
  - Acceleron

### Look to the Future: Academic Showcase

#### 15.30 Ocular Fibrosis: See Common Mechanisms in a New Light

- The non-canonical signalling pathway indicative of ocular fibrosis which is also found in IPF and renal
- Targeting the transformation to myofibroblasts, from epithelial to mesenchymal cells
- Learnings from ocular fibrosis mechanisms that share commonalities with other fibrotic conditions and discovery of shared biomarkers
The Gut as a Target for Anti-Fibrotic Therapy in NASH
- Using the gut for systemic immune modulation without immune suppression
- Generating an immune signal in the gut for re-directing the immune system in an anti-inflammatory way
- Targeting the gut microbiome for alleviation of fibrosis

TGF-beta receptor system: Linking skin fibrosis and cancer
- Role of CD109, a TGF-beta co-receptor, in fibrosis and cancer;
- Development of a CD109-based TGF-beta trap of less than 20 amino acids that decreases fibrosis in vitro and in vivo in scleroderma models
- CD109 as a powerful foe in squamous cell carcinoma
- Development of molecules to manipulate CD109 action in squamous cells carcinoma

Mechanisms and Endpoints of Intestinal Fibrosis
- Understand the role of the microbiome in intestinal fibrosis
- Determine the role of the mesenteric fat driving stricture formation
- Assess inflammation independent mechanisms of progression of intestinal fibrosis
- Discuss novel clinical trial endpoints for structuring Crohn’s disease

Blood test biomarkers indicative of scleroderma
- Gene expression and proteomic profiling of SSc for biomarker creation

Q&A Panel: Academic Spotlight

Chair’s Closing Remarks
- Refreshments will be provided at the end of the conference – stay for a chat or grab a beverage to go if you’ve got a flight to catch.

The AFDD conference is an excellent opportunity to meet with KOL in the field of fibrosis and to increase the size of your network.

Sofia Mayans, CEO, InfiCure Bio
Maximize your ROI at the only conference to bring together industry and leaders across fibrotic disciplines

**Spotlight Partner:**
TherapeutAix

TherapeutAix is a life sciences consultancy company based in Aachen, Germany, combining drug discovery and development expertise with a fully integrated R&D network, to deliver practical, cost and time effective solutions to drug discovery projects. It supports investors and project teams focus on the next step, progress the right assets through robust decision-making steps, with a clear line of sight to the next value-inflection point and the clinic. Since its formation in 2018, TherapeutAix has successfully conducted project reviews, developed strategies and operationalised programs for biotech, pharma and investors in fibrosis, NASH and other therapeutic areas.

[www.therapeutaix.com](http://www.therapeutaix.com)

**Spotlight Partner:**
Jakub Nunuk

Partnership Manager
Tel: +1617 455 4188
Email: sponsor@hansonwade.com

**Exhibition Partner:**
Biomodels LLC, a preclinical CRO, conducts predictive and translational studies for biotechnology and pharmaceutical companies in the areas of fibrosis, pulmonary and inflammatory diseases, in addition to several other clinical indications. Biomodels specializes in (non-GLP) customized efficacy studies that optimize dose, schedule, and define mechanism of action. Additionally, Biomodels’ state of the art Germ-Free and Gnotobiotic animal facility allows for the analysis of the role of the microbiota both in disease pathogenesis and in therapeutic efficacy.

[www.biomodels.com](http://www.biomodels.com)

**Why the AFDD Summit?**
The 3rd AFDD Summit is the fastest route to in-depth discussions with organizations prioritizing anti-fibrotic drug development. AFDD provides an unrivaled opportunity for your brand, your message and your reputation to be showcased in front of the leading minds of the growing ‘Fibrosis Industry’.

**Who do I get to meet?**
Gathering stakeholders and key opinion leaders, the AFDD Summit is the ultimate opportunity to position yourself as an expert in front of 100+ drug developers. Elevate your company’s standing and influence the future of anti-fibrotic drug development.

**What can the AFDD Summit do for you?**
- **Boost** your brand: engage industry decision makers; demonstrate thought leadership
- **Premium sponsorships:** to maximize the impact of your investment

**Total Breakdown of Audience by Industry**

<table>
<thead>
<tr>
<th>Industry</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Large Drug Developer</td>
<td>45%</td>
</tr>
<tr>
<td>Small and Medium Drug Developer</td>
<td>19%</td>
</tr>
<tr>
<td>Technology and Service Providers</td>
<td>33%</td>
</tr>
<tr>
<td>Research Institute</td>
<td>1%</td>
</tr>
<tr>
<td>Consultants</td>
<td>2%</td>
</tr>
</tbody>
</table>

We understand each business is different so we’ll work with you to build a bespoke partnership opportunity to fulfill your 2019/2020 business objectives.

**How is AFDD different?**
At this year’s Anti-Fibrotic Drug Development Summit, you can expect:

- **A HIGHER CALIBER OF CONVERSATIONS:** with over 10 hours of networking you’ll have more opportunities than ever for significant discussions with your key prospects
- **DEDICATED ICEBREAKER SESSIONS FROM THE START:** starting a conversation is never easy, so let us start them for you
- **INTERACTIVE SESSIONS AS STANDARD:** engage your audience in solution-focused exchanges at this year’s panel discussions, speed learning roundtables and poster session

**Get Involved at AFDD 2020**

Tel: (+1) 617 455 4188  
Mail: info@hansonwade.com

[www.afdd-summit.com](http://www.afdd-summit.com)